Periprocedural management of antithrombotic therapy in acute gastrointestinal bleeding requires individualized risk stratification to balance bleeding and thromboembolic risks.
How should antithrombotic therapy be managed in patients with acute gastrointestinal bleeding undergoing urgent endoscopy to balance bleeding and thrombotic risks?
This review provides a practical framework for balancing bleeding and thrombotic risks when managing antithrombotic therapy in patients undergoing urgent endoscopy for acute GI bleeding.
The management of antithrombotic agents in patients undergoing urgent gastrointestinal (GI) endoscopy presents a common and complex clinical challenge. The use of anticoagulants and antiplatelet therapies, especially in older patients with significant comorbidities, has increased substantially in recent decades due to the rising prevalence of cardiovascular and thromboembolic diseases. Balancing the risk of ongoing hemorrhage against the potentially life-threatening consequences of thrombosis remains a delicate and critical clinical decision. This review provides a practical, evidence-based approach to the periprocedural management of antithrombotic therapy in urgent endoscopy, particularly in the context of acute GI bleeding. We summarize the indications, pharmacokinetics, and reversal strategies for commonly used agents, including warfarin, direct oral anticoagulants (DOACs), low-molecular-weight heparin, aspirin, and P2Y12 inhibitors. Risk stratification is discussed in detail, considering both the urgency and bleeding risk of endoscopic procedures, as well as the thromboembolic risk associated with temporary drug interruption. Special considerations are given to high-risk patients, such as those with recent coronary stents, mechanical heart valves, or atrial fibrillation with elevated stroke risk scores. Close consultation and collaboration with other specialties, including cardiology and hematology, is often essential to optimize patient outcomes. Recommendations based on real-world clinical experience alongside formal guideline directives aim to support safe and timely endoscopic intervention without compromising systemic thrombotic protection, especially in emergent situations.
Papantoniou et al. (Thu,) conducted a review in Acute gastrointestinal bleeding. Periprocedural management of antithrombotic therapy was evaluated. Periprocedural management of antithrombotic therapy in acute gastrointestinal bleeding requires individualized risk stratification to balance bleeding and thromboembolic risks.